Home Cannabis CBG-dominant cannabis users report efficacy against pain and other conditions

CBG-dominant cannabis users report efficacy against pain and other conditions

by Team Inc.

2021-10-13-Users of CBG-dominant cannabis report efficacy against pain and other conditions

A team of researchers at Washington State University and the University of California at Los Angeles surveyed subjects who identified themselves as consumers of CBG-dominant cannabis products. There is still little research into this substance and its influence on certain disorders.

Those who consume cannabis and/or cannabis preparations with a high content of cannabinoid cannabigerol (CBG) for medical purposes report a positive effect with few adverse side effects. That's according to data published in the journal Cannabis of Cannabinoid Research.

How CBG . works

CBG acid is the precursor to the parent compound of the more popular cannabinoids THC and CBD. It is usually only found in small amounts in harvested cannabis plants. However, in recent years, specially bred varieties of the plant have been reported with higher concentrations of CBG, particularly in the Pacific Northwest of the United States.

A majority of survey participants said they used CBG-dominant preparations of cannabis solely for medical purposes. The respondents most often did this to reduce symptoms of anxiety, chronic pain, depression and insomnia. Most respondents described their symptoms as “much improved” or “very much improved” after using CBG-dominant cannabis, and three-quarters rated it as “superior” to their conventional medications.

“This is the first patient study of CBG use to document the self-reported efficacy of CBG-dominant cannabis,” said the researchers. Most respondents claimed to experience greater efficacy from CBG than from conventional pharmacotherapy. In addition, there were few side effects and negligible withdrawal symptoms among the group.

This study shows that CBG-dominant cannabis and related products are used by cannabis consumers. It demonstrates the urgent need for controlled trials for cannabis-based medicines. This is necessary to assess safety and efficacy based on dose, route of administration and specific therapeutic indications.

Read more norml.org (Source, EN)

Related Articles